FI84349C - Förfarande för framställning av en farmakologiskt värdefull förening - Google Patents

Förfarande för framställning av en farmakologiskt värdefull förening Download PDF

Info

Publication number
FI84349C
FI84349C FI850323A FI850323A FI84349C FI 84349 C FI84349 C FI 84349C FI 850323 A FI850323 A FI 850323A FI 850323 A FI850323 A FI 850323A FI 84349 C FI84349 C FI 84349C
Authority
FI
Finland
Prior art keywords
methyl
formula
tetrahydro
compound
carbazol
Prior art date
Application number
FI850323A
Other languages
English (en)
Finnish (fi)
Other versions
FI850323A0 (fi
FI84349B (fi
FI850323L (fi
Inventor
Ian Harold Coates
David Cedric Humber
James Angus Bell
George Blanch Ewan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848401888A external-priority patent/GB8401888D0/en
Priority claimed from GB848425959A external-priority patent/GB8425959D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI850323A0 publication Critical patent/FI850323A0/fi
Publication of FI850323L publication Critical patent/FI850323L/fi
Application granted granted Critical
Publication of FI84349B publication Critical patent/FI84349B/fi
Publication of FI84349C publication Critical patent/FI84349C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (5)

1. Förfarande för framställning av en farmakologiskt värdefui 1 förening med formeln (I)
0 R4 R3 N N (1) UOLJ v s· där R1 är en‘ väteatom eller en Ci-io alkyl-, C3-7 cykloalkyl-, C3-€ alkenyl- eller fenyl-Ci-3 alkylgrupp, R2 är en väteatom eller en C1-6 alkyl-, C3-7 cykloalkyl-, C2-6 alkenyl- eller fenyl-Ci-3 alkylgrupp och R3 och R4, som kan vara lika eller olika, avser var och en väteatom eller en C1-6 alkylgrupp och dä R2 är en väteatom eller en Ci-β alkylgrupp, den ena av grupperna R3 och R4 kan ocksä vara en fenyl-Ci-3 alkylgrupp; eller dess fysiologiskt godtagbar sait eller soivat, kännetecknat därav, att (A) den förening med den allmänna formeln (II) O J (II) (där Y är en reaktiv substituent) eller dess skyddade derivat omsätts en imidazolin med den allmänna formeln (III) 49 84 349 R4 R3 ^ ^ (III) HN ^ N V R1 eller dess salt; eller (B) en förening med formeln (IV) A^>=<r3 "jf ί"] \^N ,IV> ^ 2* (där A är väteatom eller hydroxylgrupp) eller dess salt eller skyddad derivat oxideras; eller (C) en förening med formeln (I) eller dess salt eller skyddade derivat omvandlas till en annan förening med formeln (I); eller (D) skyddsgruppen eller -grupper avlägsnas frän en skyddad form av en förening med formeln (I); och da en förening med formeln (I) erhälls som en enantiomer blandning, avskiljs blandning vid behov sä, att den önskade enantiomeren erhälls; ja/eller dä föreningen med formeln (I) är i form av sin fria bas, ombandlas vid behov den fria basen tili ett sait. Förfarande enligt patentkravet 1, kännetecknat därav, att man framställer 1.2.3.9- tetrahydro-9-metyl-3-[(2-mety1-lH-imidazol-1-yl)metyl]-4H-karbazol-4-on, 1.2.3.9- tetrahydro-3-[(2-metyl-lH-imidazol-1-yl)metyl] -9-(prop-2-eny1)-4H~karbazol-4-on; so 84349 9-cyklopenty1-1,2,3,9-tetrahydro-3-[(2-metyl-lH-imidazol- 1-y1)mety1]-4H-karbazol- 4-on; 1,2,3,9-tetrahydro-3-[2-metyl-1H-imidazo1-l-yl)metyl]-9-(prop-2-yl)-4H-karbazol-4-on eller dess fysiologiskt godtagbar salt eller soivat.
3. Förfarande enligt patentkravet 2, kännetecknat därav, att man framställer l,2,3,9-tetrahydro-9-metyl-3- [ ( 2-metyl-lH-imidazo-l-yl)metyl]-4H-karbazol-4-on i form av ett hydrokloridsalt.
4. Förfarande enligt patentkravet 2, kännetecknat därav, att man framställer hydrokloriddihydrat av 1,2,3,9-tetrahydro-9-metyl-3-[(2-metyl-1H-imidazo-1-y1)mety1]-4H-karbazol-4-on.
FI850323A 1984-01-25 1985-01-25 Förfarande för framställning av en farmakologiskt värdefull förening FI84349C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB848401888A GB8401888D0 (en) 1984-01-25 1984-01-25 Heterocyclic compounds
GB8401888 1984-01-25
GB848425959A GB8425959D0 (en) 1984-10-15 1984-10-15 Heterocyclic compounds
GB8425959 1984-10-15

Publications (4)

Publication Number Publication Date
FI850323A0 FI850323A0 (fi) 1985-01-25
FI850323L FI850323L (fi) 1985-07-26
FI84349B FI84349B (fi) 1991-08-15
FI84349C true FI84349C (sv) 1991-11-25

Family

ID=26287221

Family Applications (1)

Application Number Title Priority Date Filing Date
FI850323A FI84349C (sv) 1984-01-25 1985-01-25 Förfarande för framställning av en farmakologiskt värdefull förening

Country Status (29)

Country Link
KR (1) KR920003064B1 (sv)
AT (1) AT392276B (sv)
AU (1) AU579132B2 (sv)
BE (1) BE901576A (sv)
CA (1) CA1252793A (sv)
CH (1) CH664152A5 (sv)
CY (1) CY1479A (sv)
CZ (1) CZ404391A3 (sv)
DE (2) DE3502508A1 (sv)
DK (1) DK169521B1 (sv)
ES (3) ES8609309A1 (sv)
FI (1) FI84349C (sv)
FR (1) FR2561244B1 (sv)
GB (1) GB2153821B (sv)
GR (1) GR850219B (sv)
HK (1) HK33189A (sv)
HU (1) HU193592B (sv)
IE (1) IE57809B1 (sv)
IL (1) IL74165A (sv)
IT (1) IT1182150B (sv)
LU (2) LU85743A1 (sv)
NL (2) NL190373C (sv)
NO (2) NO164025C (sv)
NZ (1) NZ210940A (sv)
PH (1) PH22672A (sv)
PT (1) PT79890B (sv)
SE (1) SE460359B (sv)
SG (1) SG7089G (sv)
SK (1) SK404391A3 (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518742D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518741D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
US5204356A (en) * 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
GB8518745D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8617994D0 (en) * 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
AT396870B (de) * 1986-08-07 1993-12-27 Sandoz Ag Verfahren zur herstellung einer galenischen formulierung zur nasalen verabreichung von serotoninantagonisten
GB8623819D0 (en) * 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
JP2765845B2 (ja) * 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
GB8812002D0 (en) * 1988-05-20 1988-06-22 Glaxo Group Ltd Chemical compounds
US5202343A (en) * 1986-11-28 1993-04-13 Glaxo Group Limited Tricyclic ketones useful as HT3 -receptor antagonists
GB8628475D0 (en) * 1986-11-28 1987-01-07 Glaxo Group Ltd Medicaments
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
JPS63277622A (ja) * 1986-12-17 1988-11-15 グラクソ、グループ、リミテッド 医薬
DK662687A (da) * 1986-12-17 1988-06-18 Glaxo Group Ltd Anvendelse af tricycliske carbazoloner
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
DE3876006T2 (de) * 1987-04-14 1993-03-25 Glaxo Group Ltd Keton-derivate.
DE3874229T2 (de) * 1987-06-16 1993-03-25 British Tech Group Verwendung von dioxopiperidin-derivaten zur herstellung eines topischen praeparates als analgetika.
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8723157D0 (en) * 1987-10-02 1987-11-04 Beecham Group Plc Compounds
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US4939144A (en) * 1987-10-22 1990-07-03 Glaxo Group Limited Tricyclic ketone derivatives as 5-HT antagonists
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
JPH0249772A (ja) * 1988-04-07 1990-02-20 Glaxo Group Ltd イミダゾール誘導体
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
JPH0256485A (ja) * 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
US5290785A (en) * 1988-09-27 1994-03-01 Fujisawa Pharmaceutical Co., Ltd. Therapeutic agent for ischemic diseases
US5173493A (en) * 1988-09-27 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Pyridoindole derivatives and processes for preparation thereof
FR2639944B1 (fr) * 1988-12-06 1991-01-18 Adir Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
US5223625A (en) * 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
CA2012092A1 (en) * 1989-03-13 1990-09-13 Tadao Okegawa 5-ht3 receptor antagonist
DK0422154T3 (da) * 1989-04-21 1994-03-07 Sandoz Ag Terapeutisk anvendelse af 5-HT3-receptorantagonister
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917557D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
US5126343A (en) * 1989-09-11 1992-06-30 G. D. Searle & Co. N-azabicyclo [3.3.0]octane amides of aromatic acids
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
GB8928837D0 (en) * 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
EP1022025A3 (en) * 1991-06-26 2002-06-05 Sepracor, Inc. Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
ES2043535B1 (es) * 1992-03-13 1994-08-01 Vita Invest Sa Procedimiento para la obtencion de la 1,2,3,9-tetrahidro-9-metil-3-(2-metil-1h-imidazol-1-il)metil*-4h-carbazol-4-ona.
CA2106642C (en) * 1992-10-14 2005-08-16 Peter Bod Carbazolone derivatives and process for preparing the same
HU212934B (en) 1992-10-14 1996-12-30 Richter Gedeon Vegyeszet Process for producing novel alkoxalylated carbazolone derivatives
KR960700711A (ko) * 1993-03-08 1996-02-24 후지야마 아키라 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB2325408B (en) * 1994-06-28 1999-01-27 Kenneth Francis Prendergast Chewing gum formulation comprising ondansetron
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
US6365743B1 (en) 1995-10-13 2002-04-02 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
US5969137A (en) * 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
CA2371822A1 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
KR20040104654A (ko) 2002-04-29 2004-12-10 비오갈 기오기스제르갸르 알티. 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카르바졸-4-온의 제조 방법
FI6164U1 (sv) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronformer
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
ES2238001B1 (es) * 2004-01-21 2006-11-01 Vita Cientifica, S.L. Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
WO2005108392A2 (en) 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20090170872A1 (en) * 2005-07-05 2009-07-02 Orchid Research Laboratories Limited Compounds and Their Pharmaceutical Use
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
DK2432467T3 (en) 2009-05-20 2018-04-16 Inst Nat Sante Rech Med SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
CN115611864A (zh) * 2022-11-01 2023-01-17 常州兰陵制药有限公司 一种昂丹司琼类化合物及其制备方法与应用
GB202301322D0 (en) 2023-01-30 2023-03-15 Therakind Ltd Antiemetic pharmaceutical compositions for nasal delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740404A (en) * 1969-05-09 1973-06-19 American Cyanamid Co Piperidinomethylenedihydrocarbazolones
US3634420A (en) * 1969-05-09 1972-01-11 American Cyanamid Co 3(morpholinomethyl)-2 3-dihydro-carbazol-4(1h)-ones
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.

Also Published As

Publication number Publication date
FI850323A0 (fi) 1985-01-25
ES8801247A1 (es) 1987-12-16
IT8547600A0 (it) 1985-01-25
IE57809B1 (en) 1993-04-21
ES539852A0 (es) 1986-07-16
ES556101A0 (es) 1987-12-16
NL190373B (nl) 1993-09-01
GB2153821B (en) 1988-01-20
CY1479A (en) 1989-07-21
HUT37784A (en) 1986-02-28
SK277923B6 (en) 1995-08-09
DE3502508C2 (sv) 1990-05-03
LU85743A1 (fr) 1986-08-04
GR850219B (sv) 1985-05-23
SE460359B (sv) 1989-10-02
NL940009I2 (nl) 1999-05-03
SE8500368L (sv) 1985-07-26
NL190373C (nl) 1994-02-01
ATA20485A (de) 1990-08-15
AU579132B2 (en) 1988-11-17
CH664152A5 (fr) 1988-02-15
SE8500368D0 (sv) 1985-01-25
ES8708224A1 (es) 1987-10-01
NZ210940A (en) 1989-08-29
DE19375046I2 (de) 2002-10-10
GB2153821A (en) 1985-08-29
DE3502508A1 (de) 1985-08-14
IL74165A (en) 1988-11-15
AU3809785A (en) 1985-08-01
PT79890A (en) 1985-02-01
NO164025C (no) 1990-08-22
NL8500202A (nl) 1985-08-16
SK404391A3 (en) 1995-08-09
IT1182150B (it) 1987-09-30
DK35785A (da) 1985-07-26
NO164025B (no) 1990-05-14
KR920003064B1 (ko) 1992-04-13
DK35785D0 (da) 1985-01-25
FI84349B (fi) 1991-08-15
NO1994022I1 (no) 1994-11-09
NL940009I1 (nl) 1994-07-18
ES548430A0 (es) 1987-10-01
PH22672A (en) 1988-11-14
HU193592B (en) 1987-11-30
GB8501889D0 (en) 1985-02-27
BE901576A (fr) 1985-07-25
FI850323L (fi) 1985-07-26
KR850005439A (ko) 1985-08-26
NO850300L (no) 1985-07-26
DK169521B1 (da) 1994-11-21
FR2561244B1 (fr) 1988-03-04
HK33189A (en) 1989-04-28
FR2561244A1 (fr) 1985-09-20
AT392276B (de) 1991-02-25
CA1252793A (en) 1989-04-18
SG7089G (en) 1989-06-09
LU88268I2 (sv) 1994-02-03
IE850187L (en) 1985-07-25
ES8609309A1 (es) 1986-07-16
CZ404391A3 (en) 1993-04-14
PT79890B (en) 1987-02-03

Similar Documents

Publication Publication Date Title
FI84349C (sv) Förfarande för framställning av en farmakologiskt värdefull förening
US4695578A (en) 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0191562B1 (en) Tetrahydrocarbazolone derivatives
US4997831A (en) Lactam derivatives
WO1998056768A1 (fr) Derives tricycliques de pyrrole ou de pyrazole
US5563147A (en) Serotonerbic tetrahydropyridoindoles
US5849746A (en) Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists
JPH01258673A (ja) ケトン誘導体
RU2098418C1 (ru) Конденсированное производное тиазола или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность агониста 5-нт*003-рецептора на его основе
JP2000503997A (ja) 縮合した２，３―ベンゾジアゼピン誘導体及びａｍｐａ―レセプター抑制剤としての使用
HU188475B (en) Process for producing benzothiopyrano-pyridinones
IE60265B1 (en) Condensed diazepinones
US6127388A (en) Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists
US4482714A (en) Pyrazino[2&#39;,3&#39;-3,4]pyrido[1,2-a]indole derivatives
EP0072029B1 (de) Triazolobenzazepine, Verfahren und Zwischenprodukte zu deren Herstellung und diese enthaltende Arzneimittel
US4515949A (en) [2-(1H-indol-1-yl)ethyl]-2-piperazine and pyrido[1,2-a]indol-9-one as intermediates for pyrazino(2,3-3,4)pyrido(1,2-a) indoles which are useful for treating hypertension in mammals
US5994374A (en) Substituted 1-indolylpropyl-4-benzyl-tetrahydropyridine derivatives
EP0391414A2 (en) Benzazepine and benzothiazepine derivatives
US4879382A (en) Pyrido(3,4-f)pyrrolo(1,2-b)(1,2,5)triazepines
JPH0378862B2 (sv)
EP0726257B1 (en) 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepine derivatives useful for the treatment of central nervous system disorders, and benzopyrylium intermediates for their preparation
RU2081117C1 (ru) Производные лактама или их физиологические приемлемые соли или сольваты
FI89484B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva tetrahydro-2-/(imidazol-4-yl)metyl/pyrido(4,3-b)indol- och azepino-/4,3-b/indol-1-oner
PL81337B1 (en) Indolazonine and indolazecine derivs. - having pharmacological activity[FR2059489A1]
DE4120109A1 (de) 3-aryl- oder 3-hetaryl-(beta)-carboline, deren herstellung und verwendung in arzneimitteln

Legal Events

Date Code Title Description
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L59

Extension date: 20050223

FG Patent granted

Owner name: GLAXO GROUP LIMITED

MA Patent expired